Contemporary trends in utilization and outcomes of percutaneous left atrial appendage occlusion in the United States from 2016 to 2019.

Atrial fibrillation is a major cause of stroke and thromboembolism, and oral anticoagulation is the mainstay of prevention. In patients who are poor candidates for long-term anticoagulation, percutaneous left atrial appendage occlusion (pLAAO) emerged as an alternative stroke prevention strategy and was approved by the US Food and Drug Administration in 2015. We aimed to examine trends in procedural volume, resource utilization, and clinical outcomes of pLAAO from a nationally representative cohort.